- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Apogee Technology, Inc. (AMEX: ATA), an emerging micro-systems and nanotechnology company that designs, develops and commercializes medical devices and sensor products, reported today that Dr. Mark Prausnitz has joined the Company's Medical Advisory Board. Dr. Prausnitz is a Professor of Chemical and Biomedical Engineering and the Emerson-Lewis Faculty Fellow at the Georgia Institute of Technology. Dr. Prausnitz's research interests concern microneedles and other microfabricated devices for drug delivery across the skin and into the eye, as well as novel uses of ultrasound and related physical phenomena to enhance and target intracellular delivery.
Dr. Alexander Andrianov, Apogee's Vice President of Research and Development, said, "Dr. Prausnitz is one of the leading researchers in the area of microneedle drug delivery. His expertise covers not only the design and fabrication of microneedles, but encompasses basic questions of drug transport, insertion mechanics of microneedles in skin along with applied questions relating to drug and vaccine delivery. We are extremely excited to have him join our team to support the commercialization of our PyraDerm™ and other transdermal delivery solutions for FDA regulated and non regulated applications."
Dr. Prausnitz received the CAREER Young Investigator Award from the National Science Foundation; Young Investigator Award, Outstanding Pharmaceutical Paper Award and Outstanding Transdermal Drug Delivery Award from the Controlled Release Society; Curtis W. McGraw Research Award from the American Society for Engineering Education; and TR100 Young Innovator from Technology Review. Dr. Prausnitz has a B.S. (1988) from Stanford University and a Ph.D. (1994) from Massachusetts Institute of Technology. He has published more than 80 research articles, holds 15 issued or pending patents, consults for a number of companies, and serves as an expert witness.
About Apogee Technology, Inc.
Apogee Technology designs, develops and commercializes proprietary medical device and sensor products using its MEMS and nanotechnology for the medical, automotive, industrial and consumer markets. The Company is developing its PyraDerm™ solution for enhanced intradermal drug delivery and has introduced a family of pressure sensors under the Sensilica® brand. Apogee's goal is to provide value-added and cost-saving solutions for our customers and, in so doing, become a global leader in the sensor and medical device fields. For more information please visit our web site at: http://www.apogeemems.com .
PyraDerm™ and Sensilica® are trademarks of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders. Certain statements made herein that use the words "anticipate," "hope," "estimate," "project," "will," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied. Please refer to the company's risk factors as set forth in the Company's filings with the Securities and Exchange Commission, including its reports on Forms 10-KSB and 10-QSB.
For more information, please click here
Apogee Investor Contact:
Premier Funding & Financial Marketing
Copyright © Market WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016
Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Are humans the new supercomputer?Today, people of all backgrounds can contribute to solving serious scientific problems by playing computer games. A Danish research group has extended the limits of quantum physics calculations and simultaneously blurred the boundaries between mac April 14th, 2016